Results 131 to 140 of about 121,431 (264)

Neurological implications of chimeric antigen receptor-T cell therapy. [PDF]

open access: yesBMJ Neurol Open
Raffoul DG   +15 more
europepmc   +1 more source

Real time in vivo efficacy monitoring of desialylation and perforation enhanced immunotherapy of cancer

open access: yesBMEMat, EarlyView.
A multifunctional nanomedicine is designed to engineer NK cells for enhanced cancer immunotherapy through perforation and desialylation, enabling real‐time monitoring of ATP and GrB levels for precise efficacy assessment. Abstract Efficient enhanced NK cell therapy is of critical importance in the immune treatment of cancer.
Yuanjiao Yang   +8 more
wiley   +1 more source

Armored chimeric antigen receptor T-cell therapy targets antigen-heterogeneous glioma. [PDF]

open access: yesCancer Res
Clubb JD   +12 more
europepmc   +1 more source

Integrated spherical nucleic acid nanoreactor mobilizes targeted PD‐L1 proteolysis and cuproptosis for robust breast cancer immunotherapy

open access: yesBMEMat, EarlyView.
This study provides an integrated spherical nucleic acid nanoreactor (denoted as AMCuD) for targeted PD‐L1 degradation and chemo‐dynamically enhanced cuproptosis to synergically elicit robust immunotherapy against the triple‐negative breast cancer (TNBC) growth, recurrence and metastasis.
Ningxi Li   +9 more
wiley   +1 more source

Development and characterization of chimeric antigen receptor macrophages for amyloid clearance. [PDF]

open access: yesFront Immunol
Balachandran M   +6 more
europepmc   +1 more source

Tackling cancer stemness with nanotechnology in the era of precision medicine

open access: yesBMEMat, EarlyView.
Precise customization of nanoparticles (NPs) enables active targeting of cancer stem cells (CSCs), thereby improving drug delivery and therapeutic efficacy. NP‐based probing enhances CSC detection through imaging and liquid biopsy, whereas diverse therapeutic payloads improve therapeutic outcomes.
Shaolei Guo   +9 more
wiley   +1 more source

Status and future of recombinant adeno‐associated virus vector manufacturing

open access: yesBiotechnology Progress, EarlyView.
Abstract Sixty years of adeno‐associated virus (AAV) research illustrates a trajectory marked by basic science exploration, iterative innovation, persistent challenges, a number of clinical setbacks, as well as commercial therapeutic triumphs. This continual evolution has led to recombinant AAV (rAAV) becoming a cornerstone of modern gene therapy ...
Frank Agbogbo, David Dismuke
wiley   +1 more source

Engineering chimeric antigen receptor CD4 T cells for Alzheimer's disease. [PDF]

open access: yesProc Natl Acad Sci U S A
Boskovic P   +8 more
europepmc   +1 more source

Model‐Based Analysis with Mechanistic Insights to CAR‐T‐Cell Therapy Kinetics: Case Study with Axicabtagene Ciloleucel and Brexucabtagene Autoleucel

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Model‐informed drug development is increasingly used to support chimeric antigen receptor (CAR)‐T‐cell therapy programs. However, most population pharmacokinetic (PK) CAR‐T‐cell models available in literature are variations of an empirical piecewise‐linear model, which accurately describes the observed data but lacks a mechanistic foundation.
Anna M. Mc Laughlin   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy